All Clinical Trials
Mater conducts clinical trials in a range of therapeutic areas including Cancer, Nerouology, Medicine, Orthopaedics Surgery and Acute Care, and Mothers' and Babies Health. Clinical trials are an essential component of helathcare. They provide the evidence to evaluate the safety and efficacy of new treantments and diagnositics, and provide alternative treatment options for patients with unmet needs.
Phase 3 Study of Revumenib in Combination with Intensive Chemotherapy in Newly Diagnosed NPM1-mutated AML
SNDX-6352-0506 - Axatilimab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Axatilimab is a “monoclonal antibody”, which is an antibody manufactured in a laboratory. It is designed to specifically block a protein believed to be involved in lung fibrosis. By blocking this protein, Axatilimab may slow or stop the progression of IPF.
Assessing the use of Stomal Sponge's to reduce the frequency of neonatal stoma-bag leakage
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Do you have Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression?
Do you have Chrohn's disease?
A post-marketing study of UPadacitinib evaluating speed of onset and durability of effectiveness for patients with moderate to severe Crohn’s disease for 3 years in the real-world
A study looking at bowel healing for patients
Do you have metastatic , HER2 negative breast cancer?
The purpose of this study is to evaluate the safety and effectiveness of gedatolisib at treating your cancer when combined with other cancer drugs, compared to the standard of care for people with breast cancer.
Whistle-PF a new oral treatment for patients with Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF) or non-IPF Progressive Pulmonary Fibrosis (PPF)
Do you have generalised epilespy?
This study is trialing a novel anti-epileptic medication called XEN1101 in patients who suffer from primary generalized tonic-clonic seizures and have not achieved satisfactory seizure control using standard therapies.